Schwab Charles Investment Management Inc. lifted its holdings in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 9.2% in the second quarter, according to its most recent filing with the SEC. The firm owned 334,017 shares of the biopharmaceutical company’s stock after acquiring an additional 28,173 shares during the period. Schwab Charles Investment Management Inc. owned approximately 0.45% of Inovio Pharmaceuticals worth $2,619,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in the company. American International Group Inc. lifted its holdings in Inovio Pharmaceuticals by 7.1% during the 1st quarter. American International Group Inc. now owns 40,856 shares of the biopharmaceutical company’s stock valued at $270,000 after purchasing an additional 2,695 shares during the last quarter. Teachers Advisors LLC lifted its holdings in Inovio Pharmaceuticals by 2.3% during the 1st quarter. Teachers Advisors LLC now owns 151,775 shares of the biopharmaceutical company’s stock valued at $1,005,000 after purchasing an additional 3,411 shares during the last quarter. Bank of America Corp DE lifted its holdings in Inovio Pharmaceuticals by 14.6% during the 1st quarter. Bank of America Corp DE now owns 28,256 shares of the biopharmaceutical company’s stock valued at $188,000 after purchasing an additional 3,605 shares during the last quarter. Metropolitan Life Insurance Co. NY lifted its holdings in Inovio Pharmaceuticals by 8.5% during the 1st quarter. Metropolitan Life Insurance Co. NY now owns 51,573 shares of the biopharmaceutical company’s stock valued at $341,000 after purchasing an additional 4,020 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its holdings in Inovio Pharmaceuticals by 3.6% during the 1st quarter. Bank of New York Mellon Corp now owns 342,348 shares of the biopharmaceutical company’s stock valued at $2,266,000 after purchasing an additional 11,765 shares during the last quarter. 24.83% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This article was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.watchlistnews.com/schwab-charles-investment-management-inc-has-2-62-million-stake-in-inovio-pharmaceuticals-inc-ino/1646814.html.

Several equities analysts recently issued reports on INO shares. HC Wainwright set a $13.00 price target on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Friday, July 7th. Citigroup Inc. started coverage on shares of Inovio Pharmaceuticals in a report on Wednesday, September 6th. They set a “buy” rating and a $10.00 price target for the company. Zacks Investment Research raised shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price target for the company in a report on Tuesday, July 11th. Aegis reissued a “buy” rating and set a $14.00 price target on shares of Inovio Pharmaceuticals in a report on Tuesday, July 18th. Finally, Maxim Group reaffirmed a “buy” rating and issued a $12.00 target price on shares of Inovio Pharmaceuticals in a research note on Tuesday, September 12th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and eight have given a buy rating to the stock. Inovio Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $19.16.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) opened at 6.23 on Friday. The company’s 50-day moving average is $6.22 and its 200-day moving average is $6.64. The firm’s market cap is $562.11 million. Inovio Pharmaceuticals, Inc. has a one year low of $5.28 and a one year high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. The business had revenue of $20.41 million during the quarter, compared to the consensus estimate of $16.29 million. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. The company’s revenue for the quarter was up 229.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.26) EPS. On average, analysts forecast that Inovio Pharmaceuticals, Inc. will post ($0.95) earnings per share for the current fiscal year.

Inovio Pharmaceuticals Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.